Literature DB >> 15298157

Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases.

Paul E Steele1, Peter H Tang, Antonius J DeGrauw, Michael V Miles.   

Abstract

Coenzyme Q10 (Q10) is available as an over-the-counter dietary supplement in the United States. While its use could be considered a form of alternative therapy, the medical profession has embraced the use of Q10 in specific disease states, including a series of neurologic and muscular diseases. Clinical laboratory monitoring is available for measurement of total Q10 in plasma and tissue and for measurement of redox status, ie, the ratio of reduced and oxidized forms of Q10. Many published studies have been anecdotal, in part owing to the rarity of some diseases involved. Unfortunately, many studies do not report Q10 levels, and, thus, the relationship of clinical response to Q10 concentration in plasma frequently is not discernible. Consistent laboratory monitoring of patients treated with this compound would help ease interpretation of the results of the treatment, especially because so many formulations of Q10 exist in the marketplace, each with its own bioavailability characteristics. Q10 has an enviable safety profile and, thus, is ideal to study as an adjunct to more conventional therapy. Defining patient subpopulations and characteristics that predict benefit from exogenous Q10 and defining therapeutic ranges for those particular applications are major challenges in this field.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15298157     DOI: 10.1309/0UM2V45M00M69XPX

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

Review 1.  Some observations upon biochemical causes of ataxia and a new disease entity ubiquinone, CoQ10 deficiency.

Authors:  John M Land; Simon J R Heales; Andrew J Duncan; Iain P Hargreaves
Journal:  Neurochem Res       Date:  2006-12-21       Impact factor: 3.996

2.  Oxidative stress in Niemann-Pick disease, type C.

Authors:  Rao Fu; Nicole M Yanjanin; Simona Bianconi; William J Pavan; Forbes D Porter
Journal:  Mol Genet Metab       Date:  2010-07-27       Impact factor: 4.797

Review 3.  Coenzyme Q10 Supplementation and Its Impact on Exercise and Sport Performance in Humans: A Recovery or a Performance-Enhancing Molecule?

Authors:  Franchek Drobnic; Mª Antonia Lizarraga; Alberto Caballero-García; Alfredo Cordova
Journal:  Nutrients       Date:  2022-04-26       Impact factor: 6.706

Review 4.  Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications.

Authors:  Gerwyn Morris; George Anderson; Michael Berk; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-06-13       Impact factor: 5.590

5.  Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy.

Authors:  Takashi Kasai; Takahiko Tokuda; Takuma Ohmichi; Ryotaro Ishii; Harutsugu Tatebe; Masanori Nakagawa; Toshiki Mizuno
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.